CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7170 result(s)

Nivolumab-Ipilimumab (Opdivo-Yervoy)

Last Updated: December 18, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nivolumab-ipilimumab
Indications: ​OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.

  • Brand Name: Opdivo-Yervoy
  • Manufacturer: Bristol-Myers Squibb
  • Project Number: PC0229-000
  • Project Status: Active
  • Submission Type: Initial

apomorphine hydrochloride (Kynmobi)

Last Updated: February 26, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: apomorphine hydrochloride
Indications: ​Indicated for the acute, intermittent treatment of “OFF” episodes in patients with Parkinson's disease.

  • Brand Name: Kynmobi
  • Manufacturer: Sunovion Pharmaceuticals Canada Inc.
  • Project Number: SR0650-000
  • Project Status: Active
  • Submission Type: Initial

COVID-19 Update

Last Updated: March 1, 2021
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 Evidence Portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and increasing international scientific evidence related t...

dapagliflozin (Forxiga )

Last Updated: March 1, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dapagliflozin
Indications: ​Forxiga is indicated in adults, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) to reduce the risk of CV death, hospitalization for heart failure and urgent heart failure visit, and to improve heart failure symptoms.

  • Brand Name: Forxiga
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0642-000
  • Project Status: Complete
  • Submission Type: Initial

ofatumumab (Kesimpta)

Last Updated: March 1, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ofatumumab
Indications: For the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.

  • Brand Name: Kesimpta
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0657-000
  • Project Status: Active
  • Submission Type: Initial

triheptanoin (TBC)

Last Updated: February 26, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: triheptanoin
Indications: Triheptanoin is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

  • Brand Name: TBC
  • Manufacturer: Ultragenyx Canada Inc
  • Project Number: SR0684-000
  • Project Status: Pending
  • Submission Type: Initial

tucatinib (Tukysa )

Last Updated: February 26, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: tucatinib
Indications: ​Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.

  • Brand Name: Tukysa
  • Manufacturer: Seagen Canada Inc.
  • Project Number: PC0243-000
  • Project Status: Pending
  • Submission Type: Initial

CADTH Provisional Funding Algorithms Offer Additional Support for the Implementation of Oncology Drug Reimbursement Recommendations

Published on: February 26, 2021
Result type: News

On February 25, CADTH issued our first provisional funding algorithm — a form of expert advice that supports provincial and territorial drug programs and cancer agencies in implementing our cancer drug reimbursement recommendations. CADTH can issue a provisional funding algorithm when a new recommendation in favour of reimbursement may impact t...

Bupropion for Major Depressive Disorder or Persistent Depressive Disorder - Dysthymia

Last Updated: February 25, 2021
Result type: Projects in Progress
Report Type: Summary with Critical Appraisal

This is a new CADTH project. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies. The Projects in Progress page on the CADTH website is updated on a seven to eight-day cycle. View other current Projects...